Policy Statement

Dual-energy x-ray absorptiometry (DXA) body composition studies are considered **investigational**.

Policy Guidelines

This service should be billed using the following unlisted CPT code:
- **76499**: Unlisted diagnostic radiographic procedure

Description

Using low-dose x-rays of two different energy levels, whole-body dual-energy x-ray absorptiometry (DXA) measures lean tissue mass, total and regional body fat, as well as bone density. DXA scans have become a tool for research on body composition (e.g., as a more convenient replacement for underwater weighing). This evidence review addresses potential applications in clinical care rather than research use of the technology.

Related Policies

- Bone Mineral Density Studies
- Vertebral Fracture Assessment with Densitometry

Benefit Application

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Some state or federal mandates (e.g., Federal Employee Program [FEP]) prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.

Regulatory Status

Body composition software for several bone densitometer systems has been approved by the U.S. Food and Drug Administration through the premarket approval process. They include the Lunar iDXA systems (GE Healthcare), Hologic DXA systems (Hologic), and Norland DXA systems (Swissray). Food and Drug Administration product code: KGI.

Rationale

Background

**Body Composition Measurement**

Body composition measurements can be used to quantify and assess the relative proportions of specific body compartments such as fat and lean mass (e.g., bones, tissues, organs, muscles). These measurements may be more useful in informing diagnosis, prognosis, or therapy than
standard assessments (e.g., body weight, body mass index) that do not identify the contributions of individual body compartments or their particular relationships with health and disease. While these body composition measurements have been most frequently utilized for research purposes, they may be useful in clinical settings to:

- Evaluate the health status of undernourished patients, those impacted by certain disease states (e.g., anorexia nervosa, cachexia), or those undergoing certain treatments (e.g., antiretroviral therapy, bariatric surgery).
- Evaluate the risk of heart disease or diabetes by measuring visceral fat vs total body fat.
- Assess body composition changes related to growth and development (e.g., infancy, childhood), aging (e.g., sarcopenia), and in certain disease states (e.g., HIV, diabetes).
- Evaluate patients in situations where body mass index is suspected to be discordant with total fat mass (e.g., body-building, edema).

A variety of techniques has been researched, including most commonly, anthropomorphic measures, bioelectrical impedance, and dual-energy x-ray absorptiometry (DXA). All of these techniques are based in part on assumptions about the distribution of different body compartments and their density, and all rely on formulas to convert the measured parameter into an estimate of body composition. Therefore, all techniques will introduce variation based on how the underlying assumptions and formulas apply to different populations of subjects (i.e., different age groups, ethnicities, or underlying conditions). Techniques using anthropometrics, bioelectrical impedance, underwater weighing, and DXA are briefly reviewed below.

**Anthropomorphic Techniques**

Anthropomorphic techniques for the estimation of body composition include measurements of skinfold thickness at various sites, bone dimensions, and limb circumference. These measurements are used in various equations to predict body density and body fat. Due to its ease of use, measurement of skinfold thickness is one of the most common techniques. The technique is based on the assumption that the subcutaneous adipose layer reflects total body fat but this association may vary with age and sex.

**Bioelectrical Impedance**

Bioelectrical impedance analysis is based on the relation among the volume of the conductor (i.e., human body), the conductor's length (i.e., height), the components of the conductor (i.e., fat and fat-free mass), and its impedance. Estimates of body composition are based on the assumption that the overall conductivity of the human body is closely related to lean tissue. The impedance value is then combined with anthropomorphic data to give body compartment measures. The technique involves attaching surface electrodes to various locations on the arm and foot. Alternatively, the patient can stand on the pad electrodes.

**Underwater Weighing**

Underwater weighing requires the use of a specially constructed tank in which the subject is seated on a suspended chair. The subject is then submerged in the water while exhaling. While valued as a research tool, weighing people underwater is typically not suitable for routine clinical use. This technique is based on the assumption the body can be divided into two compartments with constant densities: adipose tissue, with a density of 0.9 g/cm³, and lean body mass (i.e., muscle and bone), with a density of 1.1 g/cm³. One limitation of the underlying assumption is the variability in density between muscle and bone; e.g., bone has a higher density than muscle, and bone mineral density varies with age and other conditions. Also, the density of body fat may vary, depending on the relative components of its constituents (e.g., glycerides, sterols, glycolipids).

**Dual-energy X-ray Absorptiometry**

While the cited techniques assume two body compartments, DXA can estimate three body compartments consisting of fat mass, lean body mass, and bone mass. DXA systems use a source that generates x-rays at two energies. The differential attenuation of the two energies is used to estimate the bone mineral content and soft tissue composition. When two x-ray
energies are used, only two tissue compartments can be measured; therefore, soft tissue measurements (i.e., fat and lean body mass) can only be measured in areas in which no bone is present. DXA can also determine body composition in defined regions (i.e., the arms, legs, and trunk). DXA measurements are based in part on the assumption that the hydration of fat-free mass remains constant at 73%. Hydration, however, can vary from 67% to 85% and can vary by disease state. Other assumptions used to derive body composition estimates are considered proprietary by DXA manufacturers. The use of DXA for bone mineral density assessment in patients diagnosed with or at risk of osteoporosis is addressed separately in Blue Shield of California Medical Policy: Bone Mineral Density Studies. Vertebral fracture assessment with densitometry by DXA is addressed separately in Blue Shield of California Medical Policy: Vertebral Fracture Assessment with Densitometry.

**Literature Review**

Evidence reviews assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.

The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and clinically useful for that purpose. Evidence reviews assess the evidence on whether a test is clinically valid and clinically useful. Technical reliability is outside the scope of these reviews, and credible information on technical reliability is available from other sources.

**Dual-energy X-ray Absorptiometry as a Test to Detect Abnormal Body Composition**

**Clinical Context and Test Purpose**

The purpose of DXA body composition studies is to improve the diagnosis and management of patients who have a clinical condition associated with abnormal body composition.

The question addressed in this evidence review is: Does the use of DXA improve the net health outcome in patients with clinical conditions associated with abnormal body composition?

The following PICOs were used to select literature to inform this review.

**Patients**

The relevant population of interest are individuals with clinical conditions associated with abnormal body composition.

**Interventions**

The test being considered is DXA body composition studies administered in an outpatient setting.

**Comparators**

The following practices are currently being used to make decisions in this patient group: standard of care without DXA or an alternative method of body composition analysis.

**Outcomes**

The general outcomes of interest include symptom management and change in disease status. For patients at risk of osteoporosis, outcomes of interest would include fracture incidence. For patients with HIV who are treated with antiretroviral therapy, outcomes of interest would include lipodystrophy.

**Technically Reliable**

Assessment of technical reliability focuses on specific tests and operators and requires a review of unpublished and often proprietary information. Review of specific tests, operators, and unpublished data are outside the scope of this evidence review and alternative sources exist. This evidence review focuses on the clinical validity and clinical utility.
Clinically Valid
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Systematic Reviews
A systematic review and meta-analysis comparing the accuracy of alternative comparators vs reference standard computed tomography (CT) and magnetic resonance imaging (MRI) methods for the quantification of intra-abdominal adipose tissue (IAAT) was published by Murphy et al (2019).1 This systematic review assessed the performance of DXA for IAAT volume quantification and compared the performance of both DXA and bioelectric impedance analysis (BIA) approaches for IAAT area quantification. The American Society for Parenteral and Enteral Nutrition (ASPEN) also conducted a systematic review to evaluate the validity of relevant body composition methods in various clinical populations.2 The use of DXA, ultrasound, and BIA for body composition analysis was investigated. Fifteen studies featuring comparisons of DXA to reference standard methods (e.g., MRI and CT) were identified. Nine studies using CT or MRI to validate DXA measures of abdominal fat mass (FM) or total body FM were used for pooled analyses. Characteristics and results of studies included for meta-analysis are summarized in Tables 1 and 2.

Table 1. SR & M-A Characteristics

<table>
<thead>
<tr>
<th>Study; Subgroup</th>
<th>Dates</th>
<th>Trials</th>
<th>Participants</th>
<th>N (Range)</th>
<th>Design</th>
<th>Duration</th>
</tr>
</thead>
</table>

IAATArea

| DXA | 2012-2014 | 3 | 381 (115-135) | Cross-sectional, diagnostic test accuracy studies Retrospective studies | NR |

| BIA | 2008-2018 | 9* | 2139 (100-1006) | Cross-sectional, diagnostic test accuracy studies Retrospective studies | NR |

Table 1. SR & M-A Characteristics

<table>
<thead>
<tr>
<th>Study; Subgroup</th>
<th>Dates</th>
<th>Trials</th>
<th>Participants1</th>
<th>N (Range)</th>
<th>Design</th>
<th>Duration</th>
</tr>
</thead>
</table>

IAATArea

| DXA | 2012-2014 | 3 | 381 (115-135) | Cross-sectional, diagnostic test accuracy studies Retrospective studies | NR |

| BIA | 2008-2018 | 9* | 2139 (100-1006) | Cross-sectional, diagnostic test accuracy studies Retrospective studies | NR |
### Study; Subgroup

<table>
<thead>
<tr>
<th>Dates</th>
<th>Trials</th>
<th>Participants¹</th>
<th>N (Range)</th>
<th>Design</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elderly adult men and women evaluated by BIA and MRI at L4-L5. Elderly, middle-aged, adult, and young men and women evaluated by BIA and CT at L4-L5.</td>
<td>3410 (40-2689)</td>
<td>Cross-sectional, diagnostic test accuracy studies Retrospective studies.</td>
<td>NR</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**IAATVolume**

**DXA**

2012-2018 7**

- Included population groups:
  - Adult men and women evaluated by DXA and CT from S1 to head region.
  - Elderly adult men and women evaluated by DXA and CT from S1 to head region.
  - Women with PCOS evaluated by DXA and MRI at L3.
  - Middle-Eastern adult men and women evaluated by DXA and MRI at android region.
  - Adult men and women evaluated by DXA and MRI at L2-L3 with conversion to L1-L5.

**IAATThickness**

**US**

2010-2014 4

- Included population groups:
  - Obese women with infertility evaluated by US and CT at L4-L5.
  - Middle-aged men and women evaluated by US and CT at L2-L3.
  - Elderly adult men and women evaluated by US and MRI at L2-L3.
  - Elderly men and women evaluated by US and MRI at L4.

**Sheean et al (2019)**

2001-2013 9

- Studies:
  - With body compositions assessed in clinical populations via DXA and a reference standard method (e.g., MRI or CT) With correlation analyses.

**Sheean et al (2019)**² (ASPEN)

2001-2013 9

- Studies:
  - With body compositions assessed in clinical populations via DXA and a reference standard method (e.g., MRI or CT) With correlation analyses.

**Abdominal**

FM in any disease via DXA

2004-2013 4

- Included population groups:
  - Urban Asian Indians with type 2 diabetes.
  - Premenopausal women with anorexia nervosa.
  - Middle-aged Indian men with CVD.
  - Multiethnic cohort of men and women with HIV.

**Total FM in any disease via DXA**

2001-2013 7

- Included population groups:
  - Women with CVD.
  - Postmenopausal women with CVD.
  - Men and women with CVD sub 96.
  - Middle-aged Indian men with CVD.
  - Individuals with myosteatosis.
  - Multiethnic cohort of men and women with HIV.

Reproduction without authorization from Blue Shield of California is prohibited.
**Results following the removal of a study due to identification as an outlier.**

### Table 2. SR & M-A Results

<table>
<thead>
<tr>
<th>Study</th>
<th>Mean Difference in IAATVolume</th>
<th>Mean Difference in IAATArea</th>
<th>Mean Difference in IAATThickness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Murphy et al (2019)</td>
<td>DXA vs CT/MRI</td>
<td>BIA</td>
<td>US</td>
</tr>
<tr>
<td>Total N</td>
<td>5310</td>
<td>381</td>
<td>2139</td>
</tr>
<tr>
<td>Pooled mean difference</td>
<td>-10 (-280, 300) (cm³)</td>
<td>-11.63 (-43.12, 19.85) (cm³)</td>
<td>-0.32 (-3.82, 3.17) (cm³)</td>
</tr>
<tr>
<td>Significance of mean difference (p)</td>
<td>p = 0.808</td>
<td>p = 0.016</td>
<td>p = 0.004</td>
</tr>
<tr>
<td>Q (p)</td>
<td>99 (&lt;0.001)</td>
<td>98 (&lt;0.001)</td>
<td>94 (&lt;0.001)</td>
</tr>
<tr>
<td>Range of N</td>
<td>40-2689</td>
<td>115-135</td>
<td>100-1006</td>
</tr>
<tr>
<td>Range of pooled mean differences</td>
<td>(-451, 262) (cm³)</td>
<td>(3.78, 16.70) (cm³)</td>
<td>(-5.72, 0.96) (cm³)</td>
</tr>
<tr>
<td>DXA Subgroup Analysis</td>
<td>Mean Difference in IAATVolume by DXA and Gender</td>
<td>Mean Difference in IAATVolume by DXA and Reference Method</td>
<td></td>
</tr>
<tr>
<td>Subgroup</td>
<td>Men</td>
<td>Women</td>
<td>CT</td>
</tr>
<tr>
<td>Subgroup N (Total N)</td>
<td>1483 (3287)</td>
<td>1804 (3287)</td>
<td>377 (3410)</td>
</tr>
<tr>
<td>Pooled mean difference</td>
<td>-144.04 (-512.29, 800.38)</td>
<td>59.96 (-381.08, 492.99)</td>
<td>-41.15 (-881.96, 930.25)</td>
</tr>
<tr>
<td>Significance for subgroup comparison (p)</td>
<td>p = 0.042</td>
<td>p = 0.311</td>
<td></td>
</tr>
<tr>
<td>ρ (p)</td>
<td>95</td>
<td>90</td>
<td>100</td>
</tr>
<tr>
<td>Range of Subgroup N</td>
<td>20-1212</td>
<td>20-1477</td>
<td>109-145</td>
</tr>
<tr>
<td>Range of pooled mean differences (cm³)</td>
<td>(-43, 379)</td>
<td>(4, 143)</td>
<td>(-451, 262)</td>
</tr>
<tr>
<td>Sheean et al (2019)</td>
<td>DXA-derived Abdominal FM</td>
<td>DXA-derived Total FM</td>
<td></td>
</tr>
<tr>
<td>Total N</td>
<td>674</td>
<td>1473</td>
<td>521</td>
</tr>
<tr>
<td>Pooled random effects correlation (95% CI)</td>
<td>0.74 (0.52-0.86)</td>
<td>0.71 (0.45-0.86)</td>
<td>0.71 (0.45-0.84)</td>
</tr>
<tr>
<td>ρ (p)</td>
<td>87 (&lt;0.01)</td>
<td>98 (&lt;0.01)</td>
<td>95 (&lt;0.01)</td>
</tr>
<tr>
<td>Range of N</td>
<td>39-625</td>
<td>66-625</td>
<td>66-132</td>
</tr>
<tr>
<td>Range of individual correlations</td>
<td>(0.52-0.86)</td>
<td>(0.49-0.80)</td>
<td>(0.49-0.87)</td>
</tr>
</tbody>
</table>

### Table 1. SR & M-A Results

<table>
<thead>
<tr>
<th>Study</th>
<th>Dates</th>
<th>Trials</th>
<th>Participants</th>
<th>N (Range)</th>
<th>Design &amp; Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total FM in CVD via DXA</td>
<td>2001-2013</td>
<td>5</td>
<td>Included population groups: Men and women with CVD sub 96 (103), 92 Postmenopausal women with CVD 132, 66 Middle-aged Indian men with CVD 128</td>
<td>521 (66-132)</td>
<td>Cross-sectional, diagnostic accuracy studies Retrospective studies</td>
</tr>
</tbody>
</table>

---

ASPEN: American Society for Parenteral and Enteral Nutrition; BIA: bioelectrical impedance analysis; CT: computed tomography; CVD: cardiovascular disease; DXA: dual-energy x-ray absorptiometry; FM: fat mass; HIV: human immunodeficiency virus; IAAT: intra-abdominal adipose tissue; LoA: limits of agreement; M-A: meta-analysis; MRI: magnetic resonance imaging; NR: not reported; SD: standard deviation; SR: systematic review; US: ultrasound.

1 Key study eligibility criteria and demographics of included subgroup participants.

* 3 of 9 trials were sampled twice for a total of 12 result sets due to use of multiple techniques for IAAT quantification via BIA.

** one of eight trials was categorized as an outlier and excluded from pooled analysis.
While this analysis was primarily focused on the utilization of the different body composition methods for the management of obesity, direct effects on key health outcomes were not explored and patient populations included for analysis displayed extensive heterogeneity and largely featured healthy populations. Measurements of IAAT volume were deemed comparable to the reference methods, however, 95% limits of agreement (LoA) were wide and these results were not seen until the removal of an outlying study. Rationale for identifying the study as an outlier and removing it from the meta-analysis was limited. Prior to the removal of the outlier, the pooled mean difference was significant compared to the reference methods at -124 cm$^3$ (95% LoA: [-479, 230]; $p = 0.013$; $I^2 = 99 \, [p < 0.001]$; $Q(7) = 773$). Performance of DXA for the measurement of IAAT volume also varied significantly between male and female subgroups. Furthermore, included studies did not pre-determine clinically meaningful LoA. The authors further caution that DXA measurement of IAAT volume has the capacity to differ from reference methods by more than 100%, however, the clinical significance of these margins of error are uncertain in individuals with obesity. While IAAT area cutoff points have been described for the determination of metabolic risk and visceral obesity based on single-slice CT, the authors do not recommend utilization of DXA IAAT area measurements for this purpose due to wide LoA. The clinical utility of existing IAAT area cutpoints is also uncertain as these parameters were found to have applicability for women and cannot necessarily be extrapolated to mixed populations.

ASPEN recommends the use of DXA for the assessment of FM in patients with a specific disease or clinical outcome with a strong recommendation rating based on their analysis. Due to the lack of studies reporting on the validity of DXA for lean mass measurements, no recommendations could be made for assessments of this body compartment. The systematic review acknowledges that while the quality of the included evidence was low, the strong recommendation rating was applied with the rationale that the net benefits of FM assessment via DXA outweigh potential harms. However, the use of DXA findings to make patient management decisions and reporting of adverse events was not featured in the included studies.

Calella et al (2019) performed a systematic review exploring various methods for body composition analysis in patients with cystic fibrosis (CF). A previous systematic review by Calella et al (2018) presented on differences in body composition between patients with CF and healthy controls evaluated by DXA and other methods. DXA was most frequently used to measure lean body or fat-free mass which was significantly reduced in CF patients. While several included studies showed a correlation between lower fat-free mass and impaired pulmonary function, application, and use of this measure in patient management and its impact on health outcomes was not explored and requires further clarification. As these reviews featured qualitative analyses, data on clinical validity could not be extracted.

A systematic review by Bundred et al (2019) evaluated body composition assessment and sarcopenia in patients with pancreatic ductal adenocarcinoma. Meta-analyses revealed that sarcopenia was associated with lower overall survival in both operable (harms ratio: 1.95; 95% confidence interval: 1.35-2.81; $p < 0.001$) and unresectable patients (harms ratio: 2.49; 95% confidence interval: 1.38-4.48; $p = 0.002$). However, of the 42 included studies, only 1 utilized measurements obtained by DXA, limiting the relevance of the overall findings to this technology and preventing extraction of pertinent clinical validity data. Furthermore, the authors caution that many studies failed to account for variation introduced by gender, race, tumor stage, and other factors. Additionally, clear criteria for the diagnosis of sarcopenia or cachexia via body composition assessments with DXA are lacking.

Cross-Sectional Studies
Most of the literature on DXA as a diagnostic test to detect abnormal body composition involves the use of the technology in the research setting, often as a reference test; studies have been conducted in different populations of patients and underlying disorders. In some cases, studies have compared other techniques with DXA to identify simpler methods of determining body composition. In general, these studies have shown that DXA is highly correlated to various...
methods of body composition assessment. For example, a study by Alves et al (2014) compared 2 bioelectrical impedance devices with DXA for the evaluation of body composition in heart failure. Ziai et al (2014) compared bioelectric impedance analysis with DXA for evaluating body composition in adults with CF. Whether or not a DXA scan is considered the reference standard, the key consideration regarding its routine clinical use is whether the results of the scan can be used to manage the patients and improve health outcomes.

Case-Control Studies
As a single diagnostic measure, it is important to establish diagnostic cutoff points for normal and abnormal values. This is problematic because normal values will require the development of normative databases for the different components of body composition (i.e., bone, fat, lean mass) for different populations of patients at different ages. Regarding measuring bone mineral density (BMD), normative databases have largely focused on postmenopausal white women, and these values cannot necessarily be extrapolated to men or to different races. DXA determinations of BMD are primarily used for fracture risk assessment in postmenopausal women and to select candidates for various pharmacologic therapies to reduce fracture risk. In an example regarding lean mass, Reina et al (2019) conducted a case-control study to assess the correlation of body mass index (BMI) or serum albumin levels to DXA-derived parameters of nutritional status and sarcopenia in women (n=89) with rheumatoid arthritis. While 44% of cases met diagnostic criteria for sarcopenia based on quantification of the skeletal muscle index, a reference technique was not clearly identified in this study. Skeletal muscle index is calculated by dividing appendicular skeletal muscle mass by the square of the patient's height. A previously identified threshold of ≤5.75 kg/m² in women was applied, however, this metric was established through the use of BIA in a slightly older patient population. Given that DXA provides measures of lean mass which may be influenced by body compartments other than skeletal muscle, the relevance of this diagnostic cutoff point is uncertain. Furthermore, the study utilized a control group composed of patients affected by non-inflammatory rheumatic disorders as opposed to healthy controls, further limiting the relevance of applied cutoff points. In addition to the aforementioned uncertainties of establishing and applying normal values for components of body composition, it also is unclear how a single measure of body composition would be used in patient management. Studies discussing appropriate use and determination of DXA-derived lean mass cutoffs for sarcopenia in various populations of patients and underlying disorders continue to be featured in the literature.

Clinically Useful
A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

Direct Evidence
Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from randomized controlled trials (RCTs).

No RCTs were identified to support the utility of DXA for this indication.

Chain of Evidence
Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Because the clinical validity of DXA for this population is limited, a chain of evidence cannot be constructed.
Section Summary: DXA as a Test to Detect Abnormal Body Composition
The available evidence was generated primarily in research settings and often used DXA body composition studies as a reference standard; these studies do not permit conclusions about the accuracy of DXA for measuring body composition. A systematic review exploring the clinical validity of DXA measurements against reference methods for the quantification of intra-abdominal adipose tissue raised concerns regarding precision and reliability. Additionally, no studies were identified in which DXA body composition measurements were actively used in patient management.

DXA as a Test to Monitor Changes in Body Composition
Clinical Context and Test Purpose
The purpose of serial DXA body composition studies in patients who have a clinical condition managed by monitoring body composition changes over time is to improve disease management.

The question addressed in this evidence review is: Does serial DXA improve the net health outcome in patients with clinical conditions managed by monitoring body composition changes over time?

The following PICOs were used to select literature to inform this review.

Patients
The relevant population of interest are individuals with clinical conditions managed by monitoring body composition changes over time.

Interventions
The test being considered is serial DXA body composition studies.

Comparators
The following practices are currently being used to make decisions in this patient group: standard of care without DXA or an alternative method of body composition analysis.

Outcomes
The general outcomes of interest include symptom management and change in disease status. For patients with anorexia nervosa, outcomes of interest would include disease-related morbidity, disease-related mortality, and rate of remission.

Technically Reliable
Assessment of technical reliability focuses on specific tests and operators and requires a review of unpublished and often proprietary information. Review of specific tests, operators, and unpublished data are outside the scope of this evidence review and alternative sources exist. This evidence review focuses on the clinical validity and clinical utility.

Clinically Valid
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

The ability to detect a change in body composition over time is related in part to the precision of the technique, defined as the degree to which repeated measurements of the same variable give the same value. For example, DXA measurements of bone mass are thought to have a precision error of 1% to 3% and, given the slow rate of change in BMD in postmenopausal women treated for osteoporosis, it is likely that DXA scans would only be able to detect a significant change in BMD in the typical patient after two years of therapy. Of course, changes in body composition are anticipated to be larger and more rapid than changes in BMD in postmenopausal women; therefore, precision errors in DXA scans become less critical in interpreting results. However, precision errors for other body compartments such as lean and fat...
mass may differ and impact clinical validity. Coefficients of variation as high as 42.2% have been reported for fat mass.19.

**Prospective Studies**

Several studies have reported on DXA measurement of body composition changes over time in clinical populations; none of these studies used DXA findings to make patient management decisions and few addressed how serial body composition assessment might improve health outcomes.19-22 A long-term prospective study assessing the association between body fat and breast cancer risk in postmenopausal women with a normal BMI was published by Iyengar et al. (2019), featuring the ad hoc secondary analysis of results from the Women's Health Initiative randomized clinical trial and observational study cohorts.22 Women (n=3460) were assessed at baseline and during years 1, 3, 6, and 9 for BMI and via DXA. Multivariable-adjusted hazard ratios for the association of various body fat measures with the risk of developing invasive or estrogen receptor positive breast cancer were reported. Median follow-up duration was 16.9 years. Characteristics and results of clinical validity for breast cancer risk assessment are summarized in Tables 3 and 4.

**Table 3. Study Characteristics of Clinical Validity of Risk Assessment**

<table>
<thead>
<tr>
<th>Study</th>
<th>Study Population</th>
<th>Design*</th>
<th>Reference Standard</th>
<th>Timing of Reference and Index Tests</th>
<th>Blinding of Assessors</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iyengar et al (2019)</td>
<td>Postmenopausal women aged 50 to 79 years enrolled in the Women's Health Initiative (WHI) RCT or observational study were considered for study. Women from 3 WHI trial centers were assessed longitudinally for body fat composition. Data from women with normal BMIs were assessed for correlations with breast cancer outcomes.</td>
<td>Prospective, sample selection NR.</td>
<td>Clinical outcomes were confirmed via questionnaires. Breast cancer cases were confirmed via review of medical records and pathology reports.</td>
<td>NR</td>
<td>NR</td>
<td>Risk outcomes for women in the RCT and observational cohorts were not analyzed separately. Given that treatments utilized in the RCT group may have had an impact on breast cancer risk and outcomes, the relevance and utility of this study is uncertain.</td>
</tr>
</tbody>
</table>

BMI: body mass index; NR: not reported; RCT: randomized controlled trial.

a Note 2 aspects of design: prospective, retrospective or nonconcurrent prospective and sample selection random or consecutive

b Note other characteristics that could cause bias or limit relevance such as timeframe or practice setting.

**Table 4. Clinical Validity of Breast Cancer Risk Assessment with DXA**

<table>
<thead>
<tr>
<th>Study Subgroup; Body Fat DXA Measurement (Cutoff)</th>
<th>Initial N</th>
<th>Final N</th>
<th>Excluded Samples</th>
<th>Prevalence of Condition</th>
<th>Clinical Validity Outcome: Multivariable Adjusted HR (95% CI)</th>
<th>Baseline Body Fat Measures</th>
<th>Serial Body Fat Measures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whole-body fat mass, kg (&gt;25.1)</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>57</td>
<td>1.89 (1.21-2.95)</td>
<td>0.004</td>
<td></td>
</tr>
<tr>
<td>Whole-body fat, % (&gt;41.3)</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>52</td>
<td>1.79 (1.14-2.83)</td>
<td>0.03</td>
<td></td>
</tr>
</tbody>
</table>

Reproduction without authorization from Blue Shield of California is prohibited
These results suggest that standard BMI categorization may be inadequate for the risk assessment of invasive breast cancers in postmenopausal women. However, the clinical utility of DXA findings on patient management protocols and health outcomes requires further study. Relevance and study design and conduct limitations are summarized in Tables 5 and 6.

Table 5. Relevance Limitations

<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Outcomes</th>
<th>Duration of Follow-Up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iyengar et al (2019)</td>
<td>1, 4. Study population is unclear; study population not representative of intended use.</td>
<td>2. Version used unclear regarding both DXA and patient participation in RCT treatment or observational groups.</td>
<td>3. Not compared to other tests used for same purpose.</td>
<td>3, 5. Key clinical validity outcomes not reported; adverse events of the test not described.</td>
<td></td>
</tr>
</tbody>
</table>

DXA: dual-energy x-ray absorptiometry; RCT: randomized controlled trial.

Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.

Intervention key: 1. Classification thresholds not defined; 2. Version used unclear; 3. Not intervention of interest.

Comparator key: 1. Classification thresholds not defined; 2. Not compared to credible reference standard; 3. Not compared to other tests in use for same purpose.

Outcomes key: 1. Study does not directly assess a key health outcome; 2. Evidence chain or decision model not explicated; 3. Key clinical validity outcomes not reported (sensitivity, specificity, and predictive values); 4. Reclassification of diagnostic or risk categories not reported; 5. Adverse events of the test not described (excluding minor discomforts and inconvenience of venipuncture or noninvasive tests).

Follow-Up key: 1. Follow-up duration not sufficient with respect to natural history of disease (true-positives, true-negatives, false-positives, false-negatives cannot be determined).
Table 6. Study Design and Conduct Limitations

<table>
<thead>
<tr>
<th>Study</th>
<th>Selectiona</th>
<th>Blindingb</th>
<th>Delivery of Testc</th>
<th>Selective Reportingd</th>
<th>Data Completenesse</th>
<th>Statisticalfe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iyengar et al (2019)22</td>
<td>1. Selection not described.</td>
<td>1. Blinding not described.</td>
<td>1, 4. Timing of delivery of index or reference tests not clear; expertise of evaluators not described.</td>
<td>2. Evidence of selective reporting (covariates did not have to be pre-specified).</td>
<td>1. Inadequate description of indeterminate and missing samples.</td>
<td>2. Comparison with other tests not reported.</td>
</tr>
</tbody>
</table>

a Selection key: 1. Selection not described; 2. Selection not random or consecutive (i.e., convenience).
b Blinding key: 1. Not blinded to results of reference or other comparator tests.
c Test Delivery key: 1. Timing of delivery of index or reference test not described; 2. Timing of index and comparator tests not same; 3. Procedure for interpreting tests not described; 4. Expertise of evaluators not described.
e Data Completeness key: 1. Inadequate description of indeterminate and missing samples; 2. High number of samples excluded; 3. High loss to follow-up or missing data.
f Statistical key: 1. Confidence intervals and/or p values not reported; 2. Comparison with other tests not reported.

Clinically Useful
A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

Direct Evidence
Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

No RCTs were identified to support the utility of DXA for this indication.

Chain of Evidence
Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Because the clinical validity of DXA for this population cannot be established, a chain of evidence cannot be constructed.

Section Summary: DXA as a Test to Monitor Changes in Body Composition
Studies assessing serial DXA used it as a tool to measure body composition and were not designed to assess the accuracy of DXA. None of the studies used DXA findings to make patient management decisions or addressed how serial body composition assessment might improve health outcomes.

Summary of Evidence
For individuals who have a clinical condition associated with abnormal body composition who receive DXA body composition studies, the evidence includes systematic reviews and several cross-sectional studies comparing DXA with other techniques. The relevant outcomes are symptoms and change in disease status. The available studies were primarily conducted in research settings and often used DXA body composition studies as a reference standard; these studies do not permit conclusions about the accuracy of DXA for measuring body composition. A systematic review exploring the clinical validity of DXA measurements against reference methods for the quantification of intra-abdominal adipose tissue raised concerns for precision and reliability. More importantly, no studies were identified in which DXA body composition
measurements were actively used in patient management. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have a clinical condition managed by monitoring changes in body composition over time who receive serial DXA body composition studies, the evidence includes several prospective studies monitoring patients over time. The relevant outcomes are symptoms and change in disease status. The studies used DXA as a tool to measure body composition and were not designed to assess the accuracy of DXA. None of the studies used DXA findings to make patient management decisions or addressed how serial body composition assessment might improve health outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes.

Supplemental Information
Practice Guidelines and Position Statements

International Society for Clinical Densitometry
The International Society for Clinical Densitometry (2015) updated its statements on the use of dual X-ray absorptiometry (DXA) for body composition. The following statements were made on the use of DXA for total body composition with regional analysis:
• To assess fat distribution in patients with HIV who are using antiretroviral agents known to increase the risk of lipoatrophy.
• To assess fat and lean mass changes in obese patients undergoing bariatric surgery (or medical, diet, or weight loss regimens with anticipated large weight loss) when weight loss exceeds approximately 10%. The statement noted that the impact of DXA studies on clinical outcomes in these patients is uncertain.
• To assess fat and lean mass in patients with muscle weakness and poor physical functioning. The impact on clinical outcomes is uncertain.

Of note, pregnancy is a contraindication to use of DXA to measure body composition. The statement also adds that the clinical utility of DXA measurements of adiposity and lean mass (e.g., visceral adipose tissue, lean mass index, fat mass index) is uncertain. Furthermore, while the use of DXA adiposity measures such as fat mass index may be useful in risk-stratifying patients for cardio-metabolic outcomes, specific thresholds to define obesity have not been established.

International Conference on Sarcopenia and Frailty Research Task Force
Evidence-based clinical practice guidelines for the screening, diagnosis, and management of sarcopenia were developed by the International Conference on Sarcopenia and Frailty Research task force in 2018. The following recommendations were made:
• Screening for sarcopenia can be performed using gait speed analysis or SARC-F questionnaire.
• Individuals screened as positive for sarcopenia should be referred for further assessment to confirm the presence of the disease.
• DXA imaging should be used to determine low levels of lean body mass when diagnosing sarcopenia.

The recommendation regarding the diagnostic use of DXA received a conditional (weak) recommendation. The certainty of the evidence for DXA assessment was ranked low due to:
• DXA studies featuring populations from low-middle income countries are lacking.
• DXA measurement of lean body mass rather than muscle mass may potentially misclassify body composition in certain individuals.
• Incorporation of DXA measurements of lean body mass may have limited additional benefit for the prediction of relevant health outcomes (e.g., falls, fractures, lowered physical performance, mobility).
U.S. Preventive Services Task Force Recommendations
No U.S. Preventive Services Task Force recommendations for whole-body DXA have been identified.

Medicare National Coverage
There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials
A search of ClinicalTrials.gov in July 2019 did not identify any ongoing or unpublished trials that would likely influence this review.

References


Documentation for Clinical Review

- No records required

Coding

This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms of the Policy. Inclusion or exclusion of codes does not constitute or imply member coverage or provider reimbursement.

IE

The following services may be considered investigational.

<table>
<thead>
<tr>
<th>Type</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT®</td>
<td>76499</td>
<td>Unlisted diagnostic radiographic procedure</td>
</tr>
<tr>
<td>HCPCS</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>ICD-10</td>
<td>BW0KZZZ</td>
<td>Plain Radiography of Whole Body</td>
</tr>
<tr>
<td>Procedure</td>
<td>BW0LZZZ</td>
<td>Plain Radiography of Whole Skeleton</td>
</tr>
</tbody>
</table>
Policy History

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

<table>
<thead>
<tr>
<th>Effective Date</th>
<th>Action</th>
<th>Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>04/05/2007</td>
<td>BCBSA Medical Policy adoption</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>01/07/2011</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>06/30/2015</td>
<td>Coding update</td>
<td>Administrative Review</td>
</tr>
<tr>
<td>10/30/2015</td>
<td>Policy title change from Whole Body Dual X-Ray Absorptiometry (DEXA) to Determine Body Composition</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>03/01/2016</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>06/01/2017</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>11/01/2017</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>11/01/2018</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>12/01/2019</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
</tbody>
</table>

Definitions of Decision Determinations

Medically Necessary: A treatment, procedure, or drug is medically necessary only when it has been established as safe and effective for the particular symptoms or diagnosis, is not investigational or experimental, is not being provided primarily for the convenience of the patient or the provider, and is provided at the most appropriate level to treat the condition.

Investigational/Experimental: A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.

Split Evaluation: Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.

Prior Authorization Requirements (as applicable to your plan)

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member's health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member's eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.

Questions regarding the applicability of this policy should be directed to the Prior Authorization Department. Please call (800) 541-6652 or visit the provider portal at www.blueshieldca.com/provider.

Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield reserves the right to review and update policies as appropriate.